PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study-Reference-Cited by-同舟云学术

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

Published:2015-03 Issue:3 Volume:16 Page:284-292
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Moskowitz Alison J,Schöder Heiko,Yahalom Joachim,McCall Susan J,Fox Stephanie Y,Gerecitano John,Grewal Ravinder,Hamlin Paul A,Horwitz Steven,Kobos Rachel,Kumar Anita,Matasar Matthew,Noy Ariela,Palomba M Lia,Perales Miguel-Angel,Portlock Carol S,Sauter Craig,Shukla Neerav,Steinherz Peter,Straus David,Trippett Tanya,Younes Anas,Zelenetz Andrew,Moskowitz Craig H

Publisher

Elsevier BV

Subject

Oncology

Reference22 articles.

1. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned;Viviani;N Engl J Med,2011

2. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial;Linch;Lancet,1993

3. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial;Schmitz;Lancet,2002

4. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model;Moskowitz;Blood,2001

5. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease;Josting;Ann Oncol,2002

Cited by 232 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma;JCO Oncology Practice;2024-09-12

2. Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2024-09-06

3. Fifteen year Follow-up of Relapsed/ Refractory Patients with Hodgkin Lymphoma Treated with Autologous Hematopoietic Stem Cell Transplantation;Journal of Stem Cell Therapy and Transplantation;2024-07-02

4. What is the best salvage therapy for Hodgkin lymphoma?;Current Opinion in Oncology;2024-06-20

5. The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era;Seminars in Hematology;2024-06